A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Christopher Lieu,  MD

Christopher Lieu, MD

Study ID

Protocol Number: 21-4633

More information available at ClinicalTrials.gov: NCT04717375

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers